source
- Capricor sues Nippon Shinyaku over pricing dispute for Duchenne cell therapy candidateCapricor Therapeutics announced it has filed a lawsuit against its Japanese partner Nippon Shinyaku. The suit alleges a flaw in the pricing terms of the distribution and commercialization agreemen…
- Angelini to acquire Catalyst Pharmaceuticals for $4.1 billion, adding rare CNS drug portfolioAngelini Pharma announced it will purchase Catalyst Pharmaceuticals in a cash transaction valued at about $4.1 billion. The agreement pays $31.50 per Catalyst share, representing a 21% premium to…